Preliminary program

The program will be updated continuously with more information. 


October 24

 12.30 - 17.00
   
11.30-12.30 Lunch
   
12.30-12.45 Introduction by the Editor in chief at JIM
Bo Angelin
   
12.45 - 13.00 Welcome
Ulf Smith and James L. Kirkland
   

Session 1

Contribution by cellular senescence and other mechanisms to metabolic dysfunction 

Chair: Tamara Tchkonia

 
13.00-13.30

Age is not enough to identify increased CS in man

Tamara Tchkonia, USA 

   
13.30 - 14.00

Developing new senolytic therapies - an update

James L. Kirkland, USA

   
14.00 - 14.30

Human pharmacokinetic and pharmacodynamic studies of senolytics: the case of fisetin

Jan Nehlin, Denmark

   
14.30 - 15.00 Coffee
   
15.00 - 15.30

Cell senescence in human metabolic cells and possibilities for senolytic therapy

Ulf Smith, Sweden

   
15.30 - 16.00

Targeting seno-anergy to treat age-related disease

Tohru Minamino, Japan

   
16.00 - 16.30

Functional rehabilitation of senescent pancreatic islets

Cristina Aguayo-Mazzucato, USA

   
16.30 - 17.00

Round table discussion

Recorder: Rosa Spinelli

October 25

 08.30-17.00
   

Session 2

Contribution of cellular senescence and other aging mechanisms to metabolic co- morbidities 

Chair: Thomas von Zglinicki

 
08.30 - 09.00

Role of cell senescence in obesity

Allyson K. Palmer, USA

   
09.00 - 09.30

Adipocyte senescence in humans

Kirsty Spalding, Sweden

   
09.30 - 10.00

Role of cell senescence and senolytic therapy in NAFLD/NASH

Stijn Meijnikman, Holland

   
10.00 - 10.30

Metabolism as a targetable vulnerability of senescent cells

Thomas von Zglinicki, UK 

   
10.30 - 11.00 Coffee
   
11.00 - 11.30

Round Table Discussion

Recorder: Allyson Palmer

   

Session 3

Senolytics as preventive agents and treatments for metabolic disease 

Chair: Nicolas Musi

 
11.30 - 12.00 

Gerotherapeutics for conditions associated with aging and the metabolic syndrome

Iman Al-Naggar, USA

   
12.00 - 12.30

Analysis of senescence in human adipose tissue using single nuclei
RNAseq

Nicolas Musi, USA

   
12.30 - 13.30 Lunch
   

Session 4

And for diabetic complications 

Chair: Nicolas Musi

 
13.30 - 14.00

Targeting senescence in the diabetic heart

Georgina Ellison, USA 

   
14.00 - 14.30

Diabetic eye complications

Brittni Scruggs, USA

   
14.30 - 15.30 Coffee
   
15.30 - 16.00

Unlocking the potential of topical senolytics for chronic diabetic wounds

Saranya Wyles, USA

   
16.00 - 16.30

Senolytic therapy for peripheral artery disease

Mary M. McDermott, USA 

   
16.30 - 17.00

Round Table Discussion:

Recorder: Saranya Wyles

   

October 26

09.00 - 12.00
   

Session 5

Novel prosenescent, senomorphic, and senolytic agents

Chair: Barbara B. Kahn

   
09.00 - 09.30

Hyperinsulinemia and new anti-diabetic agents target metabolic cell senescence

Rosa Spinelli, Italy

   
09.30 - 10.00

Novel signaling lipids which prevent and reverse pancreatic islet cell senescence

Barbara B. Kahn, USA 

   
10.00 - 10.30

Senosensitizers - a novel class of agents

James L. Kirkland, USA

   
10.30 - 11.30

General discussion

Lead by: James L. Kirkland and Ulf Smith.

   
12.00 Lunch and farewell